Septerna names SEP-204 as development candidate for Graves' disease
Tweet Send to a Friend
Septerna, Inc. (Nasdaq: SEPN) has selected SEP-204 as a development candidate for the treatment of Graves' disease and thyroid eye ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




